Patients with chronic kidney disease (CKD) are at a high risk for cardiovascular disease (CVD), and approximately half of all deaths among patients with CKD are a direct result of CVD. The premature cardiovascular disease extends from mild to moderate CKD stages, and the severity of CVD and the risk of death increase with a decline in kidney function. Successful kidney transplantation significantly decreases the risk of death relative to long-term dialysis treatment; nevertheless, the prevalence of CVD remains high and is responsible for approximately 20-35% of mortality in renal transplant recipients. The prevalence of traditional and nontraditional risk factors for CVD is higher in patients with CKD and transplant recipients compared with the general population; however, it can only partly explain the highly increased cardiovascular burden in CKD patients. Nontraditional risk factors, unique to CKD patients, include proteinuria, disturbed calcium and phosphate metabolism, anemia, fluid overload, and accumulation of uremic toxins. This accumulation of uremic toxins is associated with systemic alterations including inflammation and oxidative stress which are considered crucial in CKD progression and CKD-related CVD. Kidney transplantation can mitigate the impact of some of these nontraditional factors, but they typically persist to some degree following transplantation. Taking into consideration the scarcity of data on uremic waste products, oxidative stress, and their relation to atherosclerosis in renal transplantation, in the review, we discussed the impact of uremic toxins on vascular dysfunction in CKD patients and kidney transplant recipients. Special attention was paid to the role of native and transplanted kidney function.

1. Introduction

Patients with chronic kidney disease (CKD) are at a high risk for cardiovascular disease (CVD), and approximately half of all deaths among patients with CKD are a direct result of CVD. Premature cardiovascular disease extends from mild to moderate stages of CKD, and the severity of CVD and the risk of death increase with a decline in kidney function [1–3].

Moreover, the nature and spectrum of cardiovascular disease in CKD are recognized to be different from that in people without kidney disease including atherosclerosis, arteriosclerosis, calcific arterial and valve disease, left ventricular remodeling and dysfunction, arrhythmia, and sudden cardiac death.

Successful kidney transplantation significantly decreases the risk of death relative to long-term dialysis treatment [4]. Nevertheless, the prevalence of cardiovascular disease in this population is high and is responsible for approximately 20-35% of mortality in renal transplant recipients [5].

The prevalence of traditional and nontraditional risk factors for CVD is higher in patients with CKD compared with the general population; however, it can only partly explain such sorely increased cardiovascular burden in CKD patients [2, 6]. Nontraditional risk factors, unique to CKD patients, include proteinuria, disturbed calcium and phosphate metabolism, anemia, fluid overload, and accumulation of uremic toxins. This accumulation of uremic toxins is associated with systemic alterations including inflammation and...
oxidative stress which are considered crucial in the progression of CKD-related CVD.

Kidney transplantation can mitigate the impact of some of these nontraditional risk factors, but they typically persist to some degree following transplantation. The restoration of renal function favorably modifies cardiovascular risk in transplant recipients, and each 5 ml/min/1.73 m² increase in eGFR is associated with a 15% reduction in cardiovascular disease and mortality [7]. However, some specific for this population factors, such as immune activation and immunosuppressant agents, may be involved in the increased cardiovascular risk of cardiovascular disease [5].

2. Uremic Toxins

The progressive loss of kidney function is accompanied by the retention of plenty of metabolites, due to a decrease in their renal clearance and/or a rise in production. Many of these solutes have been shown to exert biological activity, thereby affecting the functioning of cells and affecting metabolic processes, resulting in the uremic syndrome. Generally, they may originate from endogenous metabolism, be produced by microbial metabolism, or be ingested from an endogenous source. According to the European Uremic Toxin Work Group (EUtox) organic uremic toxins are classified according to their physicochemical properties and possibilities of removal by dialysis [8]:

1. Small, water-soluble molecules with a maximum molecular weight (MW) of 500 Da which can be easily removed by dialysis; molecules in this group include, i.a., guanidines (asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA)), oxalate, methylamines (trimethylamine-N-oxide (TMAO)), polyamines, urea, carbamylated compounds, and purines

2. Middle molecules—small proteins or peptides with MW ≥ 500 Da, although most of them have MW > 10000 Da. They are often expressed in response to other toxins (e.g., cytokines), and their concentration depends both from retention and on endocrine and paracrine mechanisms. Dialytic removal of middle molecules is possible with membranes with a large enough pore size used in either diffusive or convective mode. Compounds in this group include angiotensin, atrial natriuretic peptide (ANP), β₁-microglobulin, complement factors D and Ba, cytokines (IL-6, IL-18, IL-1β, and TNFα), endothelin, fibroblast growth factor-23 (FGF-23), modified lipids and lipoproteins, pentraxin-3, VEGF, and parathyroid hormone

3. Protein-bound molecules—the heterogeneous group of generally low MW solutes, which due to their protein binding are difficult to remove by dialysis; many of these molecules are generated by the intestine microbiota; the main compounds in this group are advanced glycation end products (AGEs), cresols (p-cresyl sulfate, p-cresyl glucuronide), hippurates, homocysteine, indoles (indoxyl sulfate, indole acetic acid), kynurenines, and phenols (phenylacetic acid) [8]

Accumulating data suggest that uremic toxins contribute substantially to the development and severity of cardiovascular disease in CKD patients. Table 1 summarizes the mechanisms of action of selected uremic toxin impact on cardiovascular damage.

3. Atherosclerosis in Chronic Kidney Disease

Accumulating data suggest that atherosclerosis starts from early stages of CKD and remaining high as CKD progresses [33]. CKD-related endothelial dysfunction plays an important role in the development of atherosclerosis [34, 35]. It is characterized by increased oxidative stress, expression of proinflammatory and prothrombotic molecules, and decreased capabilities of endothelial repair. Uremic toxins can contribute to these deleterious effects on the endothelium [36–38]. There is a correlation between inflammation, oxidative stress, endothelial dysfunction, and markers of vasculopathy and kidney function [39–41].

The vascular toxicity of uremic toxins has been demonstrated in clinical studies among chronic kidney disease, dialysis, and kidney transplant patients. Decreased kidney function impacts the levels of these solutes and may be a relevant confounder when the association between uremic toxins and hard cardiovascular outcomes is studied. The factors potentially contributing to atherosclerosis in CKD patients are presented in Figure 1.

4. Uremic Toxins and Kidney Function

4.1. Protein-Bound Uremic Toxins. Protein-bound uremic toxins (pUTs)—p-cresyl sulfate (p-CS), p-cresyl glucuronide (p-CG), indoxyl sulfate (IxS), and indole-3-acetic acid (IAA)—originate from the metabolism of the intestinal microbiota of aromatic amino acids (tyrosine, phenylalanine, and tryptophan) [42–44]. In the distal colon segment, tryptophan is converted into indole and IAA, and tyrosine and phenylalanine into p-cresol. In the colon mucosa and liver, p-cresol is partly detoxified into p-CS and p-CG, and indole into IxS [42–44]. In blood, pUTs bind on serum albumin [45] are removed by the kidneys—free fraction by glomerular filtration and protein-bound via tubular secretion [43, 44].

The serum levels of pUTs are inversely related to renal function, and the serum concentrations increase progressively with the progression of CKD in adults and pediatric CKD patients [44, 46–51]. It was demonstrated that free and total fractions of toxins increase progressively from early stages of CKD with significantly higher concentrations in later stages [44, 46–48, 51]. Total and free fractions of p-CS and IxS correlate inversely with eGFR [46–48] and are comparable in patients on peritoneal dialysis and hemodialysis [48]. In dialyzed patients, residual renal function substantially contributes to uremic toxin levels both in patients on maintenance hemodialysis and peritoneal dialysis [52, 53]. Together with the loss of kidney function serum concentrations, there is a rise in uremic toxin levels [52, 53].
Few studies evaluated the levels of pbUTs in transplanted patients [51, 54–56]. In prospective studies by Liaeuf et al. [51, 55] and Poesen et al. [54], it was demonstrated that serum levels of IxS, IAA, and p-CS decreased significantly within a few days and then remained stable during 12 months after transplantation. Moreover, the levels of pbUTs in transplanted subjects were even lower than in controls with comparable kidney function. The cause of this phenomenon remains unclear. The possible explanations of these findings are the changes in gut microbiota after transplantation and the impact of immunosuppressant agents and antibiotics [57].

### 4.2. Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA)

Serum levels of ADMA and SDMA are elevated in patients with CKD [58, 59]. For SDMA, renal excretion is the major pathway of elimination, and SDMA levels are closely related to eGFR. The kidneys also play a central role in the elimination of ADMA; however, the removal of ADMA takes place both by excretion in the urine and by degradation by dimethylarginine dimethylaminohydrolase (DDAH) and transamination by alanine glyoxylate aminotransferase 2 (AGXT2), enzymes primarily expressed in the kidneys. This may explain why in patients with
autosomal dominant polycystic kidney disease or kidney diseases with proteinuria, ADMA levels arise earlier and are highly independent on eGFR [60].

The data on levels of ADMA and SDMA in renal transplant patients are scarce and somewhat inconsistent. Most often, plasma ADMA levels demonstrated a biphasic course after successful kidney transplantation with a transient rise in the immediate postoperative period followed by a subtle decline in the weeks; however, the change did not correlate with improvement of graft function. ADMA levels remained elevated compared with CKD patients, matched for age and comorbidities [61–64]. A potential explanation of the increase of ADMA levels in the posttransplant period may be the effect of methylarginine release triggered by surgery, ischemia/reperfusion injury, and the catabolic effect of corticosteroids [61, 64, 65]. The persistence of increased levels may be related to activation of the immune system [61, 66] and metabolic side effects of immunosuppressive agents (calcineurin inhibitors and corticosteroids) [67, 68].

4.4. Phosphate, Klotho, and FGF23. Abnormalities of mineral metabolism are universal complications of CKD associated with accelerated atherosclerosis and vascular calcification and correlated with increased mortality across all stages of CKD, independent of traditional risk factors [84–86]. The levels of serum phosphate, calcium, and parathyroid hormone are influenced by α-Klotho, FGF23, 1,25-dihydroxyvitamin D, diet, and medications, interacting with each other in complicated ways.

α-Klotho not only functions as one of the regulators of mineral homeostasis but also exerts pleiotropic biological effects including antioxidative stress, antiapoptosis, and antiaging [87, 88]. α-Klotho is expressed in multiple tissues; however, the strongest expression is in the kidney [89]. Kidney injury and subsequent renal impairment will result in the decrease of α-Klotho production. It has been shown that serum α-Klotho starts to decline in stage 2 CKD, and urinary α-Klotho even earlier, in stage 1 CKD [90], and for each 1 ml/min/1.73m² eGFR decrease, an adjusted mean decrease of 3.2 pg/ml of serum α-Klotho was revealed [91]. Furthermore, pbUTs inhibit α-Klotho expression [92]. Clinical and experimental studies have shown that the decrease of α-Klotho is positively associated with eGFR [87, 93, 94].

Fibroblast growth factor 23 (FGF23) is a bone-derived phosphatonin, which acts in the kidney to induce urinary phosphate excretion and suppress 1,25-dihydroxyvitamin D synthesis, in the presence of FGF receptor 1 (FGFR1) and its coreceptor α-Klotho [95, 96]. It has been also shown that FGF23 has a deleterious effect on vascular function—endothelial dysfunction, atherosclerosis, left ventricular hypertrophy, and increased risk of major cardiovascular events [97–99].

The increase in FGF23 is a compensatory reaction in response to decreased expression of transmembrane α-Klotho to maintain mineral homeostasis, so in early stages of CKD, serum phosphates are not elevated. In turn, increased levels of FGF23 decrease α-Klotho expression, and finally, dietary phosphorus overload cannot be compensated and contributes to overt hyperphosphatemia in advanced stages of CKD [96]. FGF23 levels increase progressively in early stages of CKD. It is suggested that renal injury itself may be an initial stimulus for FGF23 secretion [100]. In Isakova et al.’s [101] study, 33% of participants with eGFR ≥ 70 ml/min and 85% with eGFR 30–60 ml/min had elevated levels of FGF23, and in a dialyzed patient, serum levels of FGF23 are extremely high reaching levels that can be 1000-fold above the normal range [101]. Moreover, a strong correlation between eGFR and FGF23 was revealed [91, 101].
Close to 90% of patients with 3-4 CKD stage have normal phosphate levels, and with the progressive loss of functional nephrons, the compensatory mechanism is overwhelmed, and most patients with ESRD have overt hyperphosphatemia. Hyperphosphatemia is considered to be a risk factor for cardiovascular and all-cause mortality, and for each 1 mg/dl increase in serum phosphate, the risk of death is increased by 18-20% [102, 103].

The data on levels of α-Klotho and FGF23 in transplant recipients are scarce, and sometimes inconsistent. During the first week after kidney transplantation, the decrease in serum levels of α-Klotho was noted [104, 105]. This initial decline is probably multifactorial and may be a response to trauma and tissue injury, transient kidney tubular dysfunction, and the impact of immunosuppression therapy [104, 106]. In the consecutive weeks, the gradual increase of α-Klotho was observed with the highest levels exhibited at 52 weeks posttransplantation and compared with pretransplant levels [104]. However, no association between serum α-Klotho levels and kidney function has not been demonstrated in Tan et al.’s study, as well as in three other cross-sectional studies [107–109].

FGF23 levels decline in the postrenal transplantation period; however, they remain higher than in CKD patients matched for eGFR [104, 110–113]. Further reductions in FGF23 levels are observed over longer follow-up, approximating normal levels 1–3 years after transplantation [110].

In up to 90% of transplant recipients, mild to moderate hypophosphatemia is present. Phosphate levels remain low for longer than in patients with CKD matched for the eGFR [114]. Kidney function does not play a crucial role in posttransplant hypophosphatemia but persistently high levels of FGF23 and PTH [113, 115].

4.5. Oxidative Stress: The Impact of Kidney Function. Oxidative stress (OS) is defined as a state of imbalance between excessive prooxidant activities relative to antioxidant defense mechanisms. Oxidative stress leads to metabolic dysregulation and oxidation of lipids, proteins, and nucleic acids and oxidative damage in cells, tissues, and organs caused by ROS and reactive nitrogen species (RNS) [116, 117]. OS is frequently observed in CKD patients; contributes to inflammation, endothelial dysfunction, risk of atherosclerosis, and progression of CKD [118]; and is considered one of the nontraditional risk factors for cardiovascular and all-cause mortality [119, 120]. OS through generation of uremic toxins enhanced intestinal permeability to endotoxins and alteration in nitrogen handling [121–123]:

(i) Accumulation of AGEs activating transcription factors (NF-κB, AP1, and SP1) executed via RAGE, and activation of NADPH oxidases (NOXs) which directly generate free radicals [124, 125]

(ii) Inflammation, which is spliced with OS—inflammatory cells stimulate the release of reactive species, and oxidized end products stimulate phagocytic cells to release inflammatory cytokines and ROS creating a positive feedback loop; the leading feature is the two-way interplay between NOX, NF-κB, inflammasomes, and phagocytic cells [126, 127]

(iii) Dialysis increases the state of oxidative stress, and the involved mechanisms include the use of bioincompatible membranes and fluids, contamination of dialysate with bacterial endotoxins, and occult infections [128–130]

The imbalance in oxidant-antioxidant status begins early in the course of CKD. It was shown that increased levels of NADPH-generated ROS and lower levels of the antioxidant enzymes can be revealed in patients with 1 and 2 CKD stage [124, 131–133]. Progressive loss of renal function results in increased oxidative stress and inflammation, and a positive correlation between advancing stage of CKD and increasing oxidative stress has been demonstrated [134–137]. The inverse relationship between eGFR and markers of oxidative stress was revealed in several studies [136–138], but in some, the correlation was at least weak [139]. It is possible that this difference may be a result of biomarkers used and studied populations.

Successful kidney transplantation leads to a reduction in metabolic abnormalities and significant improvement in OS-related markers. Normalization of graft function seems to be a key factor in the restoration to near-normal levels of OS biomarkers. Despite the fact that surgical procedure of kidney transplantation and ischemic injury during the procurement and organ transfer cause an oxidative burst, the improvement of OS can start immediately after transplantation [140]. Sudden cessation of blood flow during organ donation cause ischemic/hypoxic injury [141, 142]. Cold storage promotes ROS production via mitochondrial dysfunction. ROS react with other molecules, leading to oxidative damage of proteins, nucleic acids, and lipid peroxidation and contribute to cell apoptosis [143–145]. The reperfusion stage, during which blood flow is restored, leads to a burst of ROS and is regarded as the final stage of ischemic injury [141–146]. OS in kidney transplant recipients may be, at least in part, caused by the immunosuppressive therapy. Most of the currently used immunosuppressive medications, such as corticosteroids and calcineurin inhibitors (cyclosporine A and tacrolimus), may contribute to the increased OS. The prooxidant activities of tacrolimus and cyclosporine A, the indispensable parts of immunosuppressive, have been studied. Some studies reported that increased levels of malondialdehyde are a consequence of immunosuppressive therapy and that OS is induced mostly by cyclosporine A [147, 148]. Other studies, however, have not confirmed these findings [140, 149, 150]. Other factors, such as opportunistic infection or immune response to allograft, may also trigger OS in kidney transplant recipients [151].

CKD-associated OS in pretransplant phase, reperfusion injury, and increased immunosuppression are considered the key factors of continual OS during the early phase of transplantation [151–153]. Over the next days, the improvement of antioxidant status is observed along with the restoration of kidney function, reduction in metabolic abnormalities, and decrease in OS [152, 154–157]. Some controversies regarding changes in enzymatic and nonenzymatic antioxidants as well as OS
biomarkers may probably arise from the study design and different observation periods. In some studies, the increase in antioxidant systems and decrease in OS were observed already in the early posttransplant period [154–157]. In other studies, during the first 2 weeks, a significant increase in lipid peroxidation [140, 151, 158] and decrease in erythrocyte glutathione or superoxide dismutase activities were observed [159, 160]; however, in longer observation (28-day posttransplantation), the decrease in lipid peroxidation along with antioxidant system activities was revealed [140, 151, 158]. The levels of advanced oxidation protein products (AOPPs) decrease immediately after transplantation. As long as reduction in the first day may be explained by blood loss during surgery, the decrease in subsequent days confirms that successful kidney transplantation provides efficient elimination of generated ROS [154–157, 161, 162].

Most studies have shown that reestablishment of kidney function improves the OS over few weeks after transplantation [140, 154–162]. Time-dependent changes in OS biomarkers are associated with improvement in kidney function, and the levels of AOPPs and low molecular AGEs correlate inversely with creatinine clearance [140, 151, 154, 155, 157]. Normalization of graft function may restore to near-normal levels of OS biomarkers, regardless of immunosuppression used; however, achieving any level of kidney function will decrease OS level [150, 163, 164]. The reduction in OS after transplantation may be also a prognostic factor of short- and long-term graft function and CVD in this patient population [163, 165].

4.6. Implications of Uremic Toxins and Oxidative Stress to Atherosclerosis. In CKD, endothelial dysfunction and atherosclerosis are almost universal, as well as cardiovascular complications as first reported by Lindner et al. [166], who drew attention to the excessive incidence of atherosclerotic cardiovascular mortality in dialyzed patients. Various CKD-specific factors and processes are involved in endothelial dysfunction in CKD as presented in Figure 1. It is characterized by proinflammatory and prothrombotic endothelial phenotype, structural damage, impaired capabilities of protective and repair mechanisms, and increased oxidative stress. Uremic toxins, when in high concentrations in the bloodstream, play an important role in endothelial dysfunction, which in turn contributes to the pathogenesis of cardiovascular diseases, such as atherosclerosis and thrombotic events [35–39]. Each toxin can play its own role in vascular dysfunction, as presented in Table 1; however, its accumulation and coexistence potentiate the deleterious effects.

Inflammation is considered one of the main mechanisms of atherosclerosis, and CKD is a state of systemic inflammation [34, 167, 168]. It depends both on the increased synthesis and decreased elimination of mediators of inflammation, and multiple cytokines are involved in the genesis of this proinflammatory milieu in CKD [169]. Uremic toxins induce inflammation in endothelial cells (ECs) and stimulate the cross-talk between ECs and macrophages [14, 35–37]. In the response to the injury, the concentration of cytokines is increased leading to the activation of endothelial, resident vascular cells, and circulating monocytes [8, 11, 36–38]. Uremic toxins (pbUTs, phosphates, and FGF23) increase the expression of adhesion molecules (E-selectin, P-selectin, ICAM-1, and VCAM-1) promoting the infiltration of monocytes and macrophages in the activated endothelium [11, 13, 15, 16, 20, 35, 37].

Uremic toxins promote the production of ROS and decrease antioxidant defenses, resulting in oxidative stress [10, 21, 27, 118, 119, 127]. ROS activate transcription factors leading to the expression of inflammatory cytokines, as well as causing mitochondrial dysfunction, inducing cell death [117, 126, 170]. At the same time, uremic toxins inhibit late-stage autophagy, making cells more sensitive to oxidative stress and contributing to endothelial dysfunction. It may lead to atherosclerosis and arterial aging [171, 172].

Uremic toxins contribute to structural damage of ECs resulting in increased endothelial permeability. In vitro studies demonstrated that uremic toxins (pbUTs and phosphate) induce cytoskeletal remodeling, resulting in the changes in EC morphology, and lead to the rupture of cell-cell junctions damaging endothelial barrier and contributing to increased permeability [173–175]. Endothelial damage results in a release of microparticles and specific miRNAs that may further promote vascular damage. Endothelial microparticles (EMPs) are important in intracellular communication. Uremic toxins (pbUTs and phosphate) induce the formation of EMPs from endothelial cells [19, 176–178]. Uremic toxins induced EMPs show different activities: they have an antiangiogenic effect on endothelial progenitor cells impairing endothelium repair process [179], have procoagulant activity due to the production of factor Xa and tissue factor (TF) [179], enhance the proliferation of VSMC contributing to neointimal hyperplasia [180], and finally increase osteocalcin expression in ECs, VSMC, and fibroblast, which indicates vascular calcification [181]. MicroRNAs participate in the regulation of EC function modulating angiogenesis and immune response [182]. Uremic toxins upregulate miRNAs causing suppression of expression of genes responsible for endothelial homeostasis and thus contributing to EC dysfunction and apoptosis [182, 183].

Uremic toxins also cause a reduction in the number and function of endothelial progenitor cells. Protein-bound UTs and AGEs suppress the expression of transcription factors, SIRT1 and KLF2, responsible for the maintenance of endothelial homeostasis, inhibiting oxidative stress and cell senescence [182, 184, 185].

Uremic toxins contribute to the prothrombotic state of endothelium leading to an increased risk of thrombotic events, such as thromboembolism and ischemia. Furthermore, in CKD, the processes of coagulation and fibrinolysis are impaired with increased levels of tissue factor (TF), von Willebrand factor (vWF), thrombomodulin, factor VIII, and D-dimer [186]. In vitro studies demonstrated that uremic toxins (Ixs and IAA) increase the expression of TF and production of factor Xa indicating endothelial activation and procoagulant activity [179]. Uremic toxins (phosphate, Ixs, and ADMA) also decrease the production and/or bioavailability of NO which acts as an inhibitor of platelet adhesion and aggregation [187–189].
Endothelial cell integrity and function are critical to the prevention of atherosclerosis; therefore, dysfunction of endothelium is critical in the development of vascular dysfunction and progression of CVD. Nevertheless, uremic toxins participate in atherosclerosis development in many steps. They influence proliferation, migration, calcification, and senescence of VSMC [9–11, 16, 20, 23, 26, 34, 35]. They also induce chronic activation of leukocytes (monocytes and neutrophils), stimulate the leukocyte-endothelial interactions, and promote vascular wall infiltration by inflammatory cells [12–15, 34, 37, 167]. And finally, uremic toxins participate in the formation of atherosclerotic plaque and its rupture [1, 33–35].

5. Final Considerations

It would be worth to mention that AKI contributes to the initiation and progression of CKD, and vice versa CKD predisposes to AKI [190–192]. AKI and CKD are interconnected syndromes. The accumulating data from basic and clinical research indicates that renal hypoxia is associated with CKD, AKI to CKD continuum, and AKI on top of CKD. Tubulointerstitial hypoxia is a key player in the pathophysiology of CKD and AKI to CKD transition [193–198]. Capillary rarefaction after AKI episode results in tubulointerstitial fibrosis, and damaged tubular epithelial cells that fail to redifferentiate may contribute to capillary rarefaction and thus aggravating hypoxia [193, 194, 199]. Moreover, hypoxia induces diverse epigenetic changes such as chromosome conformation, DNA methylation, or histone modification [199]. The mechanisms involved in the susceptibility of AKI and impairment of recovery from AKI in CKD patients remain largely unexplained. Multiple mechanisms at epigenetic, signaling, cellular, and tissue levels may be involved [200–202]. Briefly, oxidative stress is a key mechanism in the pathogenesis and progression of CKD and impaired renal regeneration after AKI episodes. Therapeutic strategies targeting hypoxia have been shown to be effective in blocking the progression to CKD and possibly AKI protection [192, 193, 199].

In CKD, the retention of a variety of metabolites, due to a decrease in their renal clearance and/or a rise in their synthesis, is found. These compounds could be small and water soluble, lipophilic and/or protein bound, or larger and in the middle-molecule range. Several solutes have been shown to exert biological activity, on cells and metabolic processes, leading to uremic syndrome. Moreover, dietary protein breakdown, alternative sources such as environmental contact, food additives, natural stimulants (coffee and tea), herbal medicines, or addiction to psychedelic drugs, may also play a role in uremic toxicity. Slowing of the progression of CKD thereby preservation of kidney function is crucial in the removal of uremic toxins. Successful kidney transplantation with good graft function offers the best possibility to lower the levels of uremic toxins. In addition, uptake of uremic toxins in the intestine could be decreased by influencing dietary uptake, oral administration of sorbents, or administration of prebiotics or probiotics influencing intestinal flora. Moreover, changing the source of protein intake from animal-based to plant-based diet may also reduce intestinal production of uremic toxins. Other therapeutic intervention includes administration of drugs countering the biological impact of uremic solutes such as angiotensin-converting enzyme inhibitors (ACEi) which neutralize Ca influx due to SDMA [203]. Moreover, the IxS level can be decreased by rising sulfotransferase activity, responsible for indole sulfation [204].

In addition, the development of therapeutic strategies to raise α-Klotho and lower phosphate, FGF23, and other uremic toxins is of great importance as they may contribute to the decline in cardiovascular morbidity and mortality in CKD and after kidney transplantation.

Abbreviations

| Abbreviation | Full Form |
|--------------|-----------|
| ACEi | Angiotensin-converting enzyme inhibitor |
| ADMA | Asymmetric dimethylarginine |
| AGEs | Advanced glycation end products |
| AGTX2 | Alanine glyoxylate aminotransferase 2 |
| AKI | Acute kidney injury |
| ANP | Atrial natriuretic peptide |
| AP1 | Activator protein 1 |
| CKD | Chronic kidney disease |
| CKD-MBD | CKD-mineral bone disorder |
| CML | N-Carboxymethyllysine |
| CVD | Cardiovascular disease |
| DDAH | Dimethylarginine dimethylaminohydrolase |
| eGFR | Estimated glomerular filtration rate |
| ECs | Endothelial cells |
| EMP | Endothelial microparticles |
| ESRD | End-stage renal disease |
| ET-1 | Endothelin 1 |
| FGF23 | Fibroblast growth factor 23 |
| FGFR1 | Fibroblast growth factor receptor 1 |
| IAA | Indole-3-acetic acid |
| ICAM-1 | Intercellular adhesion molecule-1 |
| IL-6 | Interleukin 6 |
| IL-18 | Interleukin 18 |
| IL-1β | Interleukin 1β |
| IxS | Indoxyl sulfate |
| KLF2 | Krüppel-like factor 2 |
| NADPH | Nicotinamide adenine dinucleotide phosphate |
| NF-κB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| NO | Nitric oxide |
| NOX | NADPH oxidase |
| PAI-1 | Inhibitor of tissue plasminogen activator |
| p-CS | p-Cresyl sulfate |
| p-CG | p-Cresyl glucuronide |
| PTH | Parathyroid hormone |
| RAGE | Advanced glycation end product receptor |
| RNS | Reactive nitrogen species |
| ROS | Reactive oxygen species |
| SDMA | Symmetric dimethylarginine |
| SIRT1 | Sirtuin 1 |
| SMC | Smooth muscle cell |
| SP1 | Specificity protein 1 |
| TF | Tissue factor |
| TFPI | Tissue factor pathway inhibitor |
| TMAO | Trimethylamine-N-oxide |
TNFα: Tumor necrosis factor α
t-PA: Tissue plasminogen activator
VCAM-1: Vascular adhesion molecule-1
VEGF: Vascular endothelial cell growth factor
vWF: von Willebrand factor
VSMC: Vascular smooth muscle cells.

Data Availability
There are no supporting data.

Conflicts of Interest
The authors declare no conflict of interest.

References

[1] R. T. Gansevoort, R. Correa-Rotter, B. R. Hemmelgarn et al., “Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention,” The Lancet, vol. 382, no. 9889, pp. 339–352, 2013.

[2] M. Tonelli, S. A. Karumanchi, and R. Thadhani, “Epidemiology and mechanisms of uremia-related cardiovascular disease,” Circulation, vol. 133, no. 5, pp. 518–536, 2016.

[3] M. Mafham, J. Emberson, M. J. Landray, C. P. Wen, and C. Baigent, “Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis,” PLoS One, vol. 6, no. 10, article e25920, 2011.

[4] T. E. Pesavento, “Kidney transplantation in the context of renal replacement therapy,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 12, pp. 2035–2039, 2009.

[5] P. A. Devine, A. E. Courtney, and A. P. Maxwell, “Cardiovascular risk in renal transplant recipients,” Journal of Nephrology, vol. 32, no. 3, pp. 389–399, 2019.

[6] C. Zoccali, “Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective,” Kidney International, vol. 70, no. 1, pp. 26–33, 2006.

[7] D. E. Weiner, M. A. Carpenter, A. S. Levey et al., “Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial,” American Journal of Transplantation, vol. 12, no. 9, pp. 2437–2445, 2012.

[8] R. Vanholder, A. Pletinck, E. Schepers, and G. Glorieux, “Biochemical and clinical impact of Organic uremic retention solutes: a comprehensive update,” Toxins, vol. 10, no. 1, p. 33, 2018.

[9] P. Gross, Z. A. Massy, L. Henaut et al., “Para-cresyl sulfate acutely impairs vascular reactivity and induces vascular remodeling,” Journal of Cellular Physiology, vol. 230, no. 12, pp. 2927–2935, 2015.

[10] H. Watanabe, Y. Miyamoto, Y. Enoki et al., “P-Cresyl sulfate, a uremic toxin, causes vascular endothelial and smooth muscle cell damages by inducing oxidative stress,” Pharmacology Research & Perspectives, vol. 3, no. 1, article e00092, 2015.

[11] M. C. Chang, H. H. Chang, C. P. Chan et al., “p-Cresol affects reactive oxygen species generation, cell cycle arrest, Cytotoxicity and Inflammation/Atherosclerosis-Related modulators production in endothelial cells and mononuclear cells,” PLoS One, vol. 9, no. 12, article e114446, 2014.

[12] E. Schepers, N. Meert, G. Glorieux, J. Goeman, J. van der Eycken, and R. Vanholder, “P-cresyl sulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production,” Nephrology, Dialysis, Transplantation, vol. 22, no. 2, pp. 592–596, 2006.

[13] M. E. Suliman, A. R. Qureshi, O. Heimburger, B. Lindholm, and P. Stenvinkel, “Soluble adhesion molecules in end-stage renal disease: a predictor of outcome,” Nephrology, Dialysis, Transplantation, vol. 21, no. 6, pp. 1603–1610, 2006.

[14] A. Pletinck, G. Glorieux, E. Schepers et al., “Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall,” Journal of the American Society of Nephrology, vol. 24, no. 12, pp. 1981–1994, 2013.

[15] S. Ito, M. Osaka, Y. Higuchi, F. Nishijima, H. Ishii, and M. Yoshida, “Indoxyl Sulfate Induces Leukocyte-Endothelial Interactions through Up- regulation of E-selectin,” Journal of Biological Chemistry, vol. 285, no. 50, pp. 38869–38875, 2010.

[16] I. Six, J. Maizel, F. C. Barreto et al., “Effects of phosphate on vascular function under normal conditions and influence of the uraemic state,” Cardiovascular Research, vol. 96, no. 1, pp. 130–139, 2012.

[17] E. Shuto, Y. Taketani, R. Tanaka et al., “Dietary phosphorus acutely impairs endothelial function,” Journal of the American Society of Nephrology, vol. 20, no. 7, pp. 1504–1512, 2009.

[18] A. Peng, T. Wu, C. Zeng et al., “Adverse effects of simulated hyper- and hypo-phosphatemia on endothelial cell function and viability,” PLoS One, vol. 6, no. 8, article e23268, 2011.

[19] G. S. di Marco, M. König, C. Stock et al., “High phosphate directly affects endothelial function by downregulating annexin II,” Kidney International, vol. 83, no. 2, pp. 213–222, 2013.

[20] I. Six, H. Okazaki, P. Gross et al., “Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium,” PLoS One, vol. 9, no. 4, article e93423, 2014.

[21] B. Richter, J. Haller, D. Haßner, and M. Leifheit-Nestler, “Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells,” Pflügers Archiv - European Journal of Physiology, vol. 468, no. 9, pp. 1621–1635, 2016.

[22] N. Silswal, C. D. Touchberry, D. R. Daniel et al., “FGF23 directly impairs endothelin-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability,” American Journal of Physiology-Endocrinology and Metabolism, vol. 307, no. 5, pp. E426–E436, 2014.

[23] K. K. Stevens, E. P. McQuarrie, W. Sands et al., “Fibroblast Growth Factor 23 Predicts Left Ventricular Mass and Induces Cell Adhesion Molecule Formation,” International Journal of Nephrology, vol. 2011, Article ID 297070, 6 pages, 2011.

[24] A. Meinitzer, U. Seelhorst, B. Wellnitz et al., “Asymmetrical dimethylarginine Independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study),” Clinical Chemistry, vol. 53, no. 2, pp. 273–283, 2007.

[25] F. Scaler, J. Borlak, B. Beckmann et al., “Endogenous nitric oxide synthesis inhibitor asymmetric Dimethyl-Arginine accelerates endothelial cell senescence,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 10, pp. 1816–1822, 2004.

[26] K. Belmokhtar, J. Ortillon, S. Jaisson et al., “Receptor for advanced glycation end products: a key molecule in the genesis of chronic kidney disease vascular calcification and a
potential modulator of sodium phosphate co-transporter PIT-1 expression,” Nephrology, Dialysis, Transplantation, vol. 34, no. 12, pp. 2018–2030, 2019.

[27] M. P. Wautier, O. Chappey, S. Corda, D. M. Stern, A. M. Schmidt, and J. L. Wautier, “Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE,” American Journal of Physiology-Endocrinology and Metabolism, vol. 280, no. 5, pp. E685–E694, 2001.

[28] A. M. Schmidt, O. Horii, J. X. Chen et al., “Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes,” Journal of Clinical Investigation, vol. 96, no. 3, pp. 1395–1403, 1995.

[29] G. Rashid, S. Benchetrit, D. Fishman, and J. Bernheim, “Effect of advanced glycation end-products on gene expression and synthesis of TNF-α and endothelial nitric oxide synthase by endothelial cells,” Kidney International, vol. 66, no. 3, pp. 1099–1106, 2004.

[30] P. Quehenberger, A. Bierhaus, P. Fasching et al., “Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells,” Diabetes, vol. 49, no. 9, pp. 1561–1570, 2000.

[31] C. Sun, C. Liang, Y. Ren et al., “Advanced glycation end-products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways,” Basic Research in Cardiology, vol. 104, no. 1, pp. 42–49, 2009.

[32] Q. Chen, L. Dong, L. Wang, L. Kang, and B. Xu, “Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2,” Biochemical and Biophysical Research Communications, vol. 381, no. 2, pp. 192–197, 2009.

[33] C. Wanner, K. Aman, and T. Shoji, “The heart and vascular system in dialysis,” The Lancet, vol. 388, no. 10041, pp. 276–284, 2016.

[34] J. M. Valdivielso, D. Rodriguez-Puyol, J. Pascual et al., “Atherosclerosis in chronic kidney Disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 39, no. 10, pp. 1938–1966, 2019.

[35] J. Guo, L. Lu, Y. Hua et al., “Vasculopathy in the setting of cardiorenal syndrome: roles of protein-bound uremic toxins,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 313, no. 1, pp. H1–H13, 2017.

[36] N. Jourde-Chiche, F. Fakhouri, L. Dou et al., “Endothelium structure and function in kidney health and disease,” Nature Reviews Nephrology, vol. 15, no. 2, pp. 87–108, 2019.

[37] A. Eloueyk, B. Osta, R. Alameldinne, and D. Awad, “Uremic serum induces inflammation in cultured human endothelial cells and triggers vascular repair Mechanisms,” Inflammation, vol. 42, no. 6, pp. 2003–2010, 2019.

[38] R. S. da Cunha, A. F. Santos, F. C. Barreto, and A. E. M. Stinghen, “How do uremic toxins affect the endothelium?,” Toxins, vol. 12, no. 6, p. 412, 2020.

[39] A. Recio-Mayoral, D. Banerjee, C. Streather, and J. C. Kaski, “Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease - a cross-sectional study of predialysis, dialysis and kidney- transplantation patients,” Atherosclerosis, vol. 216, no. 2, pp. 446–451, 2011.

[40] G. Xu, K. Luo, H. Liu, T. Huang, X. Fang, and W. Tu, “The progress of inflammation and oxidative stress in patients with chronic kidney disease,” Renal Failure, vol. 37, no. 1, pp. 45–49, 2014.

[41] E. Nerpin, J. Helmersson-Karlqvist, U. Risérus et al., “Inflammation, oxidative stress, glomerular filtration rate, and albuminuria in elderly men: a cross-sectional study,” BMC Research Notes, vol. 5, no. 1, p. 537, 2012.

[42] K. Sumida and C. P. Kovesdy, “The gut - kidney - heart axis in chronic kidney disease,” Physiology International, vol. 106, no. 3, pp. 195–206, 2019.

[43] R. D. Mair, T. L. Sirich, N. S. Plummer, and T. W. Meyer, “Characteristics of colon-derived uremic solutes,” Clinical Journal of the American Society of Nephrology, vol. 13, no. 9, pp. 1398–1404, 2018.

[44] T. Gryp, K. de Paepe, R. Vanholder et al., “Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease,” Kidney International, vol. 97, no. 6, pp. 1230–1242, 2020.

[45] O. Deltombe, W. van Biesen, G. Glorieux, Z. Massy, A. Dhondt, and S. Eloot, “Exploring protein binding of uremic toxins in patients with different stages of chronic kidney disease and during hemodialysis,” Toxins, vol. 7, no. 10, pp. 3933–3946, 2015.

[46] S. Liabeuf, D. V. Barreto, F. C. Barreto et al., “Free p-cresyl sulphate is a predictor of mortality in patients at different stages of chronic kidney disease,” Nephrology, Dialysis, Transplantation, vol. 25, no. 4, pp. 1183–1191, 2010.

[47] F. C. Barreto, D. V. Barreto, S. Liabeuf et al., “Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 10, pp. 1551–1558, 2009.

[48] M. Rossi, K. Campbell, D. Johnson et al., “Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum: an observational study,” Nutrition, Metabolism, and Cardiovascular Diseases, vol. 24, no. 9, pp. 1035–1042, 2014.

[49] M. Rossi, K. L. Campbell, D. W. Johnson et al., “Protein-bound Uremic Toxins, Inflammation and Oxidative Stress: A Cross- sectional Study in Stage 3–4 Chronic Kidney Disease,” Archives of Medical Research, vol. 45, no. 4, pp. 309–317, 2014.

[50] E. Snaauwaert, W. van Biesen, A. Raes et al., “Concentrations of representative uraemic toxins in a healthy versus non-dialysis chronic kidney disease paediatric population,” Nephrology, Dialysis, Transplantation, vol. 33, no. 6, pp. 978–986, 2018.

[51] S. Liabeuf, S. M. Laville, G. Glorieux et al., “Difference in profiles of the gut-derived tryptophan metabolite indole acetic acid between transplanted and non-transplanted patients with chronic kidney disease,” International Journal of Molecular Sciences, vol. 21, no. 6, p. 2031, 2020.

[52] E. Snaauwaert, E. Holvoet, W. Van Biesen et al., “Uremic toxin concentrations are related to residual kidney function in the pediatric hemodialysis population,” Toxins, vol. 11, no. 4, p. 235, 2019.

[53] L. Viena, B. K. I. Meijers, B. Bammens, Y. Vanrenterghem, and P. Evenepoel, “Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function,” Peritoneal Dialysis International, vol. 34, no. 1, pp. 71–78, 2014.
Oxidative Medicine and Cellular Longevity

R. Poese, P. Evenpeol, H. de Looor et al., “The influence of renal transplantation on retained microbial-human co-metabolites,” Nephrology Dialysis Transplantation, vol. 31, pp. 1721–1729, 2016.

S. Liabeuf, L. Desjardins, Z. A. Massy et al., “Levels of indoxyl sulfate in kidney Transplant patients, and the relationship with hard outcomes,” Circulation Journal, vol. 80, no. 3, pp. 722–730, 2016.

S.-T. Huang, K.-H. Shu, C.-H. Cheng et al., “Serum Total_ p_ -Cresol and Indoxyl Sulfate Correlated With Stage of Chronic Kidney Disease in Renal Transplant Recipients,” Transplantation Proceedings, vol. 44, no. 3, pp. 621–624, 2012.

R. Vanholder, G. Glorieux, and Z. A. Massy, “Intestinal metabolites, chronic kidney disease and renal transplantation: enigma variations?,” Nephrology, Dialysis, Transplantation, vol. 31, no. 10, pp. 1547–1551, 2016.

B. Shi, Z. Ni, W. Zhou et al., “Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease,” European Journal of Internal Medicine, vol. 21, no. 5, pp. 444–448, 2010.

E. Oliva-Damaso, N. Oliva-Damaso, F. Rodriguez-Esparra-gon et al., “Asymmetric (ADMA) and symmetric (SDMA) Dimethylarginines in chronic kidney disease: a clinical approach,” International Journal of Molecular Sciences, vol. 20, no. 15, p. 3668, 2019.

J. T. Kielstein, S. R. Salpeter, S. M. Bode-Boeger, J. P. Cooke, and D. Fliser, “Symmetric dimethylarginine (SDMA) as endogenous marker of renal function—a meta-analysis,” Nephrology, Dialysis, Transplantation, vol. 21, no. 9, pp. 2446–2451, 2006.

K. J. Claes, B. Bammens, D. R. Kuypers et al., “Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation,” Nephrology, Dialysis, Transplantation, vol. 29, no. 10, pp. 1965–1972, 2014.

C. Fleck, F. Schweitzer, E. Karge, M. Busch, and G. Stein, “Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases,” Clinica Chimica Acta, vol. 336, no. 1-2, pp. 1–12, 2003.

M. Busch, C. Fleck, G. Wolf, and G. Stein, “Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease—possible candidates for paradoxical epidemiology?,” Amino Acids, vol. 30, no. 3, pp. 225–232, 2006.

D. Zakrzewicz, A. Zakrzewicz, S. Wilker et al., “Dimethylarginine metabolism during acute and chronic rejection of rat renal allografts,” Nephrology, Dialysis, Transplantation, vol. 26, no. 1, pp. 124–135, 2011.

Y. Nakayama, S. Ueda, S. Yamagishi et al., “Asymmetric dimethylarginine accumulates in the kidney during ische-mia/reperfusion injury,” Kidney International, vol. 85, no. 3, pp. 570–578, 2014.

C. Esposito, F. Grosjean, M. Torreggiani et al., “Increased asymmetric dimethylarginine serum levels are associated with acute rejection in kidney transplant recipients,” Transplantation Proceedings, vol. 41, no. 5, pp. 1570–1573, 2009.

C. M. Shing, R. G. Fassett, L. Brown, and J. S. Coombes, “The effects of immunosuppressants on vascular function, systemic oxidative stress and inflammation in rats,” Transplant International, vol. 25, no. 3, pp. 337–346, 2012.

G. Sahin, O. M. Akay, C. Bal, A. U. Yalcin, and Z. Gulbas, “The effect of calcineurin inhibitors on endothelial and platelet function in renal transplant patients,” Clinical Nephrology, vol. 76, no. 3, pp. 218–225, 2011.

S. J. Cho, G. Roman, F. Yeoabo, and Y. Konishi, “The road to advanced glycation end products: a mechanistic perspective,” Current Medicinal Chemistry, vol. 14, no. 15, pp. 1653–1671, 2007.

S. Arso, R. Graaff, W. van Oeveren et al., “Advanced glyca-tion end-products and skin autofluorescence in end-stage renal disease: a review,” Clinical Chemistry and Laboratory Medicine, vol. 52, no. 1, pp. 11–20, 2014.

C. Pipperi, C. Adamopoulos, G. Dalagiorgou, E. Diamanti-Kandarakis, and A. G. Papavassiliou, “Cross-talk between advanced glycation and Endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 7, pp. 2231–2242, 2012.

A. E. M. Stinghen, Z. A. Massy, H. Vlassara, G. E. Striker, and A. Boullier, “Uremic toxicity of advanced glycation end prod-ucts in CKD,” Journal of the American Society of Nephrology, vol. 27, no. 2, pp. 354–370, 2016.

S. K. Mallipattu, J. C. He, and J. Uribarri, “Role of advanced glycation Endproducts and potential therapeutic interven-tions in dialysis patients,” Seminars in Dialysis, vol. 25, no. 5, pp. 529–538, 2012.

N. Ahmed, R. Babaei-Jadidi, S. K. Howell, P. J. Beisswenger, and P. J. Thornalley, “Degradation products of proteins dam-aged by glycation, oxidation and nitration in clinical type 1 diabetes,” Diabetologia, vol. 48, no. 8, pp. 1590–1603, 2005.

N. Ahmed, R. Babaei-Jadidi, S. K. Howell, P. J. Thornalley, and P. J. Beisswenger, “Glycated and oxidized protein degra-dation products are indicators of fasting and postprandial hyperglycemia in diabetes,” Diabetes Care, vol. 28, no. 10, pp. 2465–2471, 2005.

R. Schinzl, G. Münch, A. Heidland, and K. Sebekova, “Advanced glycation end products in end-stage renal disease and their removal,” Nephron, vol. 87, no. 4, pp. 295–303, 2001.

P. J. Saulnier, K. M. Wheelock, S. Howell et al., “Advanced glycation end products predict loss of renal function and cor-relate with lesions of diabetic kidney disease in American Indians with type 2 diabetes,” Diabetologia, vol. 65, no. 12, pp. 3744–3753, 2016.

M. Kratochvilová, O. Zakiyanov, M. Kalousová, V. Křiha, T. Zima, and V. Tesář, “Associations of serum levels of advanced glycation end products with nutrition markers and anemia in patients with chronic kidney disease,” Renal Failure, vol. 33, no. 2, pp. 131–137, 2011.

R. D. Semba, L. Ferrucci, J. C. Fink et al., “Advanced glycation end products and their circulating receptors and level of kid-ney function in older community-dwelling women,” American Journal of Kidney Diseases, vol. 53, no. 1, pp. 51–58, 2009.

K. Sebeková, L. Podracká, P. Blážiček, D. Syrová, A. Heidland, and R. Schinzl, “Plasma levels of advanced glycation end products in children with renal disease,” Pediatric Nephrol-ogy, vol. 16, no. 12, pp. 1105–1112, 2001.

L. E. Crowley, C. P. Johnson, N. McIntyre et al., “Tissue advanced glycation end product deposition after kidney
transplantation,” *Nephron. Clinical Practice*, vol. 124, no. 1-2, pp. 54–59, 2013.

[82] J. W. Hartog, A. P. de Vries, S. J. Bakker et al., “Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients,” *Nephrology, Dialysis, Transplantation*, vol. 21, no. 8, pp. 2263–2269, 2006.

[83] H. Shahbaziian, S. S. Bavarsad, H. Yaghooti, S. M. Saadati, and S. Olapour, “Increased level of advanced glycation end-products in renal transplant patients is associated with decreased measured GFR and grafted kidney function,” *Journal of Nephropathology*, vol. 8, no. 1, article e03, 2019.

[84] T. Isakova, H. Xie, W. Yang et al., “Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic Kidney disease,” *JAMA*, vol. 305, no. 23, pp. 2432–2439, 2011.

[85] Y. Hou, X. Li, L. Sun, Z. Qu, L. Jiang, and Y. du, “Phosphorus and mortality risk in end-stage renal disease: a meta-analysis,” *Clinica Chimica Acta*, vol. 474, pp. 108–113, 2017.

[86] J. Bernheim and S. Benchetrit, “The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases,” *Nephrology, Dialysis, Transplantation*, vol. 26, no. 8, pp. 2433–2438, 2011.

[87] J. A. Neyra and M. C. Hu, “αKlotho and chronic kidney disease,” *Vitamins and Hormones*, vol. 101, pp. 257–310, 2016.

[88] S. Buchanan, E. Combet, P. Stenvinkel, and P. G. Shiel, “Klotho, aging, and the failing kidney,” *Frontiers in Endocrinology*, vol. 11, p. 560, 2020.

[89] M. C. Hu, M. Shi, J. Zhang et al., “Renal production, uptake, and handling of circulating αKlotho in patients with chronic kidney disease,” *Journal of the American Society of Nephrology*, vol. 27, no. 1, pp. 79–90, 2015.

[90] J. A. Neyra and M. C. Hu, “Potential application of klotho in human chronic kidney disease,” *Bone*, vol. 100, pp. 41–49, 2017.

[91] I. Pavik, P. Jaeger, L. Ebner et al., “Secretd Klotho and FGF23 in chronic kidney disease stage 1 to 5: a sequence suggested from a cross-sectional study,” *Nephrology, Dialysis, Transplantation*, vol. 28, no. 2, pp. 352–359, 2013.

[92] G.-H. Young and V.-C. Wu, “KLOTHO methylation is linked to uremic toxins and chronic kidney disease,” *Kidney International*, vol. 81, no. 7, pp. 611–612, 2012.

[93] D. Zou, W. Wu, Y. He, S. Ma, and J. Gao, “The role of klotho in chronic kidney disease,” *BMC Nephrology*, vol. 19, no. 1, 2018.

[94] Q. Wang, W. Su, Z. Shen, and R. Wang, “Correlation between soluble α-Klotho and renal function in patients with chronic kidney disease: a review and meta-analysis,” *BioMed Research International*, vol. 2018, Article ID 9481475, 12 pages, 2018.

[95] R. Domenico and B. Yuri, “Clinical Significance of FGF-23 in Patients with CKD,” *International Journal of Nephrology*, vol. 2011, Article ID 364890, 5 pages, 2011.

[96] P. Wahl and M. Wolf, “FGF23 in chronic kidney disease,” *Advances in Experimental Medicine and Biology*, vol. 728, pp. 107–125, 2012.

[97] G. Lee, R. Krishnasamy, C. M. Hawley, and D. W. Johnson, “The impact of fibroblast growth factor-23 on the cardiovascular system in chronic kidney disease,” *Expert Review of Endocrinology and Metabolism*, vol. 10, no. 6, pp. 565–568, 2015.

[98] B. Richter and C. Faul, “FGF23 actions on target tissues - with and without Klotho,” *Frontiers in Endocrinology*, vol. 9, p. 189, 2018.

[99] J. Arnlöv, A. C. Carlsson, J. Sundström et al., “Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular patholgy,” *Clinical Journal of the American Society of Nephrology*, vol. 8, no. 5, pp. 781–786, 2013.

[100] J. H. Ix, M. G. Shlipak, C. L. Wassel, and M. A. Whooley, “Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study,” *Nephrology, Dialysis, Transplantation*, vol. 25, no. 3, pp. 993–997, 2010.

[101] T. Isakova, P. Wahl, G. S. Vargas et al., “Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease,” *Kidney International*, vol. 79, no. 12, pp. 1370–1378, 2011.

[102] I. da, X. Xie, M. Wolf et al., “Serum phosphorus and progression of CKD and mortality: a meta-analysis of cohort studies,” *American Journal of Kidney Diseases*, vol. 66, no. 2, pp. 258–265, 2015.

[103] S. C. Palmer, A. Hayen, P. Macaskill et al., “Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis,” *JAMA*, vol. 305, no. 11, pp. 1119–1127, 2011.

[104] S.-J. Tan, A. Crosthwaite, D. Langford et al., “Mineral adaptations following kidney transplantation,” *Transplant International*, vol. 30, no. 5, pp. 463–473, 2017.

[105] T. Akimoto, T. Kimura, Y. Watanabe et al., “The impact of nephrectomy and renal transplantation on serum levels of soluble Klotho protein,” *Transplantation Proceedings*, vol. 45, no. 1, pp. 134–136, 2013.

[106] M. C. Hu, M. Shi, J. Zhang et al., “Renal production, uptake, and handling of Circulating αKlotho,” *Journal of the American Society of Nephrology*, vol. 27, no. 1, pp. 79–90, 2016.

[107] J. Malyszko, E. Koc-Żorawska, J. Matuszkiewicz-Rowinska, and J. Malyszko, “FGF23 and Klotho in relation to markers of endothelial dysfunction in kidney transplant recipients,” *Transplantation Proceedings*, vol. 46, no. 8, pp. 2647–2650, 2014.

[108] I. H. Bleskestad, I. S. Thorsen, G. Jonsson, Ø. Skadberg, H. Bergrem, and L. G. Göransson, “Soluble Klotho and intact fibroblast growth factor 23 in long-term kidney transplant patients,” *European Journal of Endocrinology*, vol. 172, no. 4, pp. 343–350, 2015.

[109] F. Leone, D. Lofaro, P. Gigliotti et al., “Soluble Klotho levels in adult renal transplant recipients are modulated by recombinant human erythropoietin,” *Journal of Nephrology*, vol. 27, no. 5, pp. 577–585, 2014.

[110] P. Evenepoel, B. K. Meijers, H. de Jonge et al., “Recovery of Hyperphosphatemia and renal phosphorus wasting one year after successful renal transplantation,” *Clinical Journal of the American Society of Nephrology*, vol. 3, no. 6, pp. 1829–1836, 2008.

[111] P. Evenepoel, M. Næsens, K. Claes, D. Kuypers, and Y. Vanrenterghem, “Tertiary ?Hyperphosphatemia? accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients,” *American Journal of Transplantation*, vol. 7, no. 5, pp. 1193–1200, 2007.

[112] K. Wesseling-Perry, R. C. Pereira, E. Tsai, R. Ettinger, H. Jüppner, and I. B. Salusky, “FGF23 and mineral
Oxidative Medicine and Cellular Longevity

metabolism in the early post-renal transplantation period,” *Pediatric Nephrology*, vol. 28, no. 11, pp. 2207–2215, 2013.

[113] M. Wolf, M. R. Weir, N. Kopyt et al., “A prospective cohort study of mineral metabolism after kidney transplantation,” *Transplantation*, vol. 100, no. 1, pp. 184–193, 2016.

[114] P. Evenepoel, M. Rodriguez, and M. Ketteler, “Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?,” *Seminars in Nephrology*, vol. 34, no. 2, pp. 151–163, 2014.

[115] S. Sirilak, K. Chatsrisak, A. Ingsathit et al., “Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase- dependent superoxide production in patients with early chronic kidney disease,” *Kidney International*, vol. 68, pp. S71–S75, 2005.

[116] A. Fortuño, O. Beloqui, G. San José, M. U. Moreno, G. Zalba, and J. Díez, “Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase- dependent superoxide production in patients with early chronic kidney disease,” *Kidney International*, vol. 68, pp. S71–S75, 2005.

[117] A. Modaresi, M. Nafar, and Z. Sahreraei, “Oxidative stress in chronic kidney disease,” *Irish Journal of Kidney Diseases*, vol. 9, no. 3, pp. 165–179, 2015.

[118] K. Daenen, A. Andries, D. Mekhali, and J. Díez, “Oxidative stress markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study,” *Kidney International*, vol. 75, no. 3, pp. 239–244, 2007.

[119] P. S. Tucker, A. T. Scanlan, and V. J. Dalbo, “Chronic kidney disease influences multiple systems: describing the relationship between oxidative stress, inflammation, kidney damage, and concomitant disease,” *Oxidative Medicine and Cellular Longevity*, vol. 2015, Article ID 806358, 8 pages, 2015.

[120] E. Dounoussi, E. Papavasiliou, A. Makedou et al., “Oxidative stress is progressively enhanced with advancing stages of CKD,” *American Journal of Kidney Diseases*, vol. 48, no. 5, pp. 752–760, 2006.

[121] N. Vodosek Hojs, S. Bevc, R. Ekart, and R. Hojs, “Oxidative stress markers in chronic kidney disease with emphasis on diabetic nephropathy,” *Antioxidants (Basel)*, vol. 9, no. 10, p. 925, 2020.

[122] C. M. Rebholz, T. Wu, L. L. Hamm et al., “The association of plasma fluorescent oxidation Products and chronic kidney disease: a case-control study,” *American Journal of Nephrology*, vol. 36, no. 4, pp. 297–304, 2012.

[123] B. P. Oberg, E. McMenamin, F. L. Lucas et al., “Increased prevalence of oxidative stress and inflammation in patients with moderate to severe chronic kidney disease,” *Kidney International*, vol. 65, no. 3, pp. 1009–1016, 2004.

[124] A. Vural, M. I. Yilmaz, K. Caglar et al., “Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens,” *American Journal of Nephrology*, vol. 25, no. 3, pp. 250–255, 2005.

[125] M. Kosierzadzki, J. Kuczynska, J. Piwowarska et al., “Prognostic significance of free radicals: mediated injury occurring in the kidney donor,” *Transplantation*, vol. 75, no. 8, pp. 1221–1227, 2003.
sensitivity to hydrogen peroxide in endothelial cells by impairing the autophagic flux,” *Biochemical and Biophysical Research Communications*, vol. 523, no. 1, pp. 123–129, 2020.

[172] M. O. Grootaert, L. Roth, D. M. Schrijvers, G. R. De Meyer, and W. Martinet, “Defective autophagy in atherosclerosis: to die or to senesce?,” *Oxidative Medicine and Cellular Longevity*, vol. 2018, Article ID 7687083, 12 pages, 2018.

[173] M. Vila Cuenca, J. van Bezu, R. H. Beelen, M. G. Vervloet, and P. L. Hordijk, “Stabilization of cell-cell junctions by active vitamin D ameliorates uraemia-induced loss of human endothelial barrier function,” *Nephrology, Dialysis, Transplantation*, vol. 34, no. 2, pp. 252–264, 2019.

[174] W. H. Tang, C. P. Wang, T. H. Yu et al., “Protein-bounded uremic toxin p-cresylsulfate induces vascular permeability alternations,” *Histochemistry and Cell Biology*, vol. 149, no. 6, pp. 607–617, 2018.

[175] D. A. Chistiakov, A. N. Orekhov, and Y. V. Bobryshev, “Endothelial barrier and its abnormalities in cardiovascular disease,” *Frontiers in Physiology*, vol. 6, p. 365, 2015.

[176] G. Favretto, R. S. Cunha, M. A. Dalboni et al., “Endothelial microparticles in uremia: biomarkers and potential therapeutic targets,” *Toxins*, vol. 11, no. 5, p. 267, 2019.

[177] A. Carmona, F. Guerrero, P. Buendia, T. Obrero, P. Aljama, and J. Carracedo, “Microvesicles derived from indoxyl sulfate treated endothelial cells induce endothelial progenitor cells dysfunction,” *Frontiers in Physiology*, vol. 8, p. 666, 2017.

[178] B. K. Meijers, K. Verbeke, W. Dhaen, Y. Vanrenterghem, M. F. Hoylaerts, and P. Evenepoel, “The Uremic Retention Solute p-Cresyl Sulfate and Markers of Endothelial Damage,” *American Journal of Kidney Diseases*, vol. 54, no. 5, pp. 891–901, 2009.

[179] B. Gondouin, C. Cerini, L. Dou et al., “Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway,” *Kidney International*, vol. 84, no. 4, pp. 733–744, 2013.

[180] J.-H. Ryu, H. Park, and S.-J. Kim, “The effects of indoxyl sulfate-induced endothelial microparticles on neointimal hyperplasia formation in anex vivo model,” *Annals of Surgical Treatment and Research*, vol. 93, no. 1, pp. 11–17, 2017.

[181] S. Soriano, A. Carmona, F. Triviño et al., “Endothelial damage and vascular calcification in patients with chronic kidney disease,” *The American Journal of Physiology*, vol. 307, pp. F1302–F1311, 2014.

[182] F. Shang, S. C. Wang, C. Y. Hsu et al., “MicroRNA-92a mediates endothelial dysfunction in CKD,” *Journal of the American Society of Nephrology*, vol. 28, no. 11, pp. 3251–3261, 2017.

[183] S. Li, Y. Xie, B. Yang et al., “MicroRNA-214 targets COX-2 to antagonize indoxyl sulfate (IS)-induced endothelial cell apoptosis,” *Apolipoprotein*, vol. 25, no. 1–2, pp. 92–104, 2020.

[184] J. H. Choi, K. L. Kim, W. Huh et al., “Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 24, no. 7, pp. 1246–1252, 2004.

[185] K. E. Jie, M. A. Zaikova, M. W. T. Bergevoet et al., “Progenitor cells and vascular function are impaired in patients with chronic kidney disease,” *Nephrology, Dialysis, Transplantation*, vol. 25, no. 6, pp. 1875–1882, 2010.

[186] M. J. Huang, R. B. Wei, Y. Wang et al., “Blood coagulation system in patients with chronic kidney disease: a prospective observational study,” *BMJ Open*, vol. 7, no. 5, article e014294, 2017.

[187] Z. Tumur and T. Niwa, “Indoxyl sulfate inhibits nitric oxide production and cell viability by inducing oxidative stress in vascular endothelial cells,” *American Journal of Nephrology*, vol. 29, no. 6, pp. 551–557, 2009.

[188] K. K. Stevens, L. Denby, R. K. Patel et al., “Deleterious effects of phosphate on vascular and endothelial function via disruption to the nitric oxide pathway,” *Nephrology Dialysis Transplantation*, vol. 32, article gkw252, 2016.

[189] T. Shafi, T. H. Hostetter, T. W. Meyer et al., “Serum asymmetric and symmetric dimethylarginine and morbidity and mortality in hemodialysis patients,” *American Journal of Kidney Diseases*, vol. 70, no. 1, pp. 48–58, 2017.

[190] L. S. Chawla and P. L. Kimmel, “Acute kidney injury and chronic kidney disease: an integrated clinical syndrome,” *Kidney International*, vol. 82, no. 5, pp. 516–524, 2012.

[191] D. P. Basile, J. V. Bonventre, R. Mehta et al., “Progression after AKI: understanding maladaptive repair processes to predict and identify therapeutic treatments,” *Journal of the American Society of Nephrology*, vol. 27, no. 3, pp. 687–697, 2016.

[192] L. He, Q. Wei, J. Liu et al., “AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms,” *Kidney International*, vol. 92, no. 5, pp. 1071–1083, 2017.

[193] T. Honda, Y. Hirakawa, and M. Nangaku, “The role of oxidative stress and hypoxia in renal disease,” *Kidney Research and Clinical Practice*, vol. 38, no. 4, pp. 414–426, 2019.

[194] C. P. C. Ow, J. P. Ngo, M. M. Ullah, L. H. Hilliard, and R. G. Evans, “Renal hypoxia in kidney disease: cause or consequence?,” *Acta Physiologica (Oxford, England)*, vol. 222, no. 4, article e12999, 2018.

[195] Y. Hirakawa, T. Tanaka, and M. Nangaku, “Renal hypoxia in CKD: pathophysiology and detecting methods,” *Frontiers in Physiology*, vol. 8, p. 99, 2017.

[196] S. Tanaka, T. Tanaka, and M. Nangaku, “Hypoxia and hypoxia-inducible factors in chronic kidney disease,” *Renal Replacement Therapy*, vol. 2, no. 1, p. 25, 2016.

[197] S. Tanaka, T. Tanaka, and M. Nangaku, “Hypoxia as a key player in the AKI-to-CKD transition,” *American Journal of Physiology. Renal Physiology*, vol. 307, no. 11, pp. F1187–F1195, 2014.

[198] S. Shu, Y. Wang, M. Zheng et al., “Hypoxia and hypoxia-inducible factors in kidney injury and repair,” *Cell*, vol. 8, no. 3, p. 207, 2019.

[199] D. A. Ferenbach and J. V. Bonventre, “Mechanisms of mal-adaptive repair after AKI leading to accelerated kidney ageing and CKD,” *Nature Reviews Nephrology*, vol. 11, no. 5, pp. 264–276, 2015.

[200] I. Six, N. Flissi, G. Lenglet et al., “Uremic toxins and vascular dysfunction,” *Toxins (Basel)*, vol. 12, no. 6, p. 404, 2020.

[201] G. Giorieux, E. Schepers, R. Schindler et al., “A novel bio-assay increases the detection yield of microbiological impurity of dialysate fluid, in comparison to the LAL-test,” *Nephrology, Dialysis, Transplantation*, vol. 24, no. 2, pp. 548–554, 2009.

[202] M. A. Venkatachalum, J. M. Weinberg, W. Kriz, and A. K. Bidani, “Failed tubule recovery, AKI-CKD transition, and kidney disease progression,” *Journal of the American Society of Nephrology*, vol. 26, no. 8, pp. 1765–1776, 2015.
[203] D. P. Basile, J. L. Friedrich, J. Spahic et al., “Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury,” American Journal of Physiology-Renal Physiology, vol. 300, no. 3, pp. F721–F733, 2011.

[204] M. Nangaku, Y. Hirakawa, I. Mimura, R. Inagi, and T. Tanaka, "Epigenetic changes in the acute kidney injury-to-chronic kidney disease transition," Nephron, vol. 137, no. 4, pp. 256–259, 2017.